![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CSNK2B |
Gene summary for CSNK2B |
![]() |
Gene information | Species | Human | Gene symbol | CSNK2B | Gene ID | 1460 |
Gene name | casein kinase 2 beta | |
Gene Alias | CK2B | |
Cytomap | 6p21.33 | |
Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | A0A1U9X7J2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1460 | CSNK2B | cSCC_p9 | Human | Skin | cSCC | 1.25e-09 | 2.39e-02 | -0.1991 |
1460 | CSNK2B | male-WTA | Human | Thyroid | PTC | 2.09e-44 | 3.21e-02 | 0.1037 |
1460 | CSNK2B | PTC01 | Human | Thyroid | PTC | 1.12e-09 | 2.44e-01 | 0.1899 |
1460 | CSNK2B | PTC04 | Human | Thyroid | PTC | 1.47e-05 | 6.89e-02 | 0.1927 |
1460 | CSNK2B | PTC05 | Human | Thyroid | PTC | 1.17e-15 | 1.12e+00 | 0.2065 |
1460 | CSNK2B | PTC06 | Human | Thyroid | PTC | 9.10e-24 | 8.94e-01 | 0.2057 |
1460 | CSNK2B | PTC07 | Human | Thyroid | PTC | 2.92e-51 | 8.91e-01 | 0.2044 |
1460 | CSNK2B | ATC08 | Human | Thyroid | ATC | 5.06e-09 | -6.24e-02 | 0.0541 |
1460 | CSNK2B | ATC09 | Human | Thyroid | ATC | 4.23e-12 | 1.98e-01 | 0.2871 |
1460 | CSNK2B | ATC12 | Human | Thyroid | ATC | 2.46e-13 | 3.47e-01 | 0.34 |
1460 | CSNK2B | ATC13 | Human | Thyroid | ATC | 1.50e-20 | 5.12e-01 | 0.34 |
1460 | CSNK2B | ATC1 | Human | Thyroid | ATC | 1.59e-09 | 2.43e-01 | 0.2878 |
1460 | CSNK2B | ATC2 | Human | Thyroid | ATC | 6.54e-11 | 1.03e+00 | 0.34 |
1460 | CSNK2B | ATC3 | Human | Thyroid | ATC | 1.37e-02 | 2.48e-01 | 0.338 |
1460 | CSNK2B | ATC4 | Human | Thyroid | ATC | 1.59e-13 | 5.71e-01 | 0.34 |
1460 | CSNK2B | ATC5 | Human | Thyroid | ATC | 9.55e-24 | 6.02e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
GO:00435427 | Cervix | CC | endothelial cell migration | 60/2311 | 279/18723 | 1.05e-05 | 2.33e-04 | 60 |
GO:00105944 | Cervix | CC | regulation of endothelial cell migration | 52/2311 | 232/18723 | 1.20e-05 | 2.54e-04 | 52 |
GO:00064708 | Cervix | CC | protein dephosphorylation | 60/2311 | 281/18723 | 1.33e-05 | 2.68e-04 | 60 |
GO:00310996 | Cervix | CC | regeneration | 46/2311 | 198/18723 | 1.43e-05 | 2.84e-04 | 46 |
GO:190165410 | Cervix | CC | response to ketone | 45/2311 | 194/18723 | 1.83e-05 | 3.44e-04 | 45 |
GO:004873210 | Cervix | CC | gland development | 84/2311 | 436/18723 | 1.93e-05 | 3.54e-04 | 84 |
GO:00512713 | Cervix | CC | negative regulation of cellular component movement | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
GO:005110110 | Cervix | CC | regulation of DNA binding | 31/2311 | 118/18723 | 2.91e-05 | 4.81e-04 | 31 |
GO:00400133 | Cervix | CC | negative regulation of locomotion | 76/2311 | 391/18723 | 3.47e-05 | 5.60e-04 | 76 |
GO:20001463 | Cervix | CC | negative regulation of cell motility | 71/2311 | 359/18723 | 3.47e-05 | 5.60e-04 | 71 |
GO:00303363 | Cervix | CC | negative regulation of cell migration | 68/2311 | 344/18723 | 5.11e-05 | 7.70e-04 | 68 |
GO:00436668 | Cervix | CC | regulation of phosphoprotein phosphatase activity | 18/2311 | 58/18723 | 1.40e-04 | 1.70e-03 | 18 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0502018 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0502019 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
hsa0501019 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0502219 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa04520110 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa0431012 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0502044 | Cervix | N_HPV | Prion disease | 39/349 | 273/8465 | 6.07e-12 | 4.13e-10 | 3.23e-10 | 39 |
hsa0502244 | Cervix | N_HPV | Pathways of neurodegeneration - multiple diseases | 47/349 | 476/8465 | 1.48e-08 | 3.13e-07 | 2.45e-07 | 47 |
hsa0501044 | Cervix | N_HPV | Alzheimer disease | 41/349 | 384/8465 | 1.50e-08 | 3.13e-07 | 2.45e-07 | 41 |
hsa0413724 | Cervix | N_HPV | Mitophagy - animal | 10/349 | 72/8465 | 6.84e-04 | 5.03e-03 | 3.93e-03 | 10 |
hsa0502054 | Cervix | N_HPV | Prion disease | 39/349 | 273/8465 | 6.07e-12 | 4.13e-10 | 3.23e-10 | 39 |
hsa0502254 | Cervix | N_HPV | Pathways of neurodegeneration - multiple diseases | 47/349 | 476/8465 | 1.48e-08 | 3.13e-07 | 2.45e-07 | 47 |
hsa0501054 | Cervix | N_HPV | Alzheimer disease | 41/349 | 384/8465 | 1.50e-08 | 3.13e-07 | 2.45e-07 | 41 |
hsa0413734 | Cervix | N_HPV | Mitophagy - animal | 10/349 | 72/8465 | 6.84e-04 | 5.03e-03 | 3.93e-03 | 10 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSNK2B | SNV | Missense_Mutation | novel | c.70G>A | p.Glu24Lys | p.E24K | P67870 | protein_coding | deleterious(0.01) | possibly_damaging(0.904) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CSNK2B | SNV | Missense_Mutation | novel | c.283N>A | p.Ala95Thr | p.A95T | P67870 | protein_coding | tolerated(0.18) | benign(0.035) | TCGA-S3-A6ZH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
CSNK2B | SNV | Missense_Mutation | c.608N>T | p.Ala203Val | p.A203V | P67870 | protein_coding | tolerated(0.11) | benign(0) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CSNK2B | SNV | Missense_Mutation | c.377N>G | p.Asp126Gly | p.D126G | P67870 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CSNK2B | SNV | Missense_Mutation | c.52N>A | p.Gly18Ser | p.G18S | P67870 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CSNK2B | SNV | Missense_Mutation | novel | c.553N>T | p.Pro185Ser | p.P185S | P67870 | protein_coding | deleterious(0.02) | benign(0.409) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
CSNK2B | SNV | Missense_Mutation | novel | c.638C>T | p.Thr213Met | p.T213M | P67870 | protein_coding | tolerated_low_confidence(0.13) | benign(0.033) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CSNK2B | SNV | Missense_Mutation | novel | c.295G>A | p.Glu99Lys | p.E99K | P67870 | protein_coding | deleterious(0.02) | benign(0.053) | TCGA-AX-A2HH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK2B | SNV | Missense_Mutation | c.253N>A | p.Ala85Thr | p.A85T | P67870 | protein_coding | deleterious(0.01) | probably_damaging(0.961) | TCGA-D1-A1NY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD | |
CSNK2B | SNV | Missense_Mutation | novel | c.101N>G | p.Phe34Cys | p.F34C | P67870 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E6-A1M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |